原发性胃淋巴瘤的诊断难点及治疗进展

doi:10.16352/j.issn.1001-6325.2023.09.1462

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (9): 1462-1466.doi: 10.16352/j.issn.1001-6325.2023.09.1462

原发性胃淋巴瘤的诊断难点及治疗进展

代娣, 刘玉琴^*

中国医学科学院基础医学研究所北京协和医学院基础学院病理学系,北京 100005

收稿日期:2022-09-23 修回日期:2023-02-20 出版日期:2023-09-05 发布日期:2023-09-01
通讯作者: ^*liuyuqin@pumc.edu.cn
基金资助:
中国医学科学院医学与健康科技创新工程-重大协同创新项目(2021-I2M-1-053)

Diagnostic difficulties and treatment progress of primary gastric lymphoma

DAI Di, LIU Yuqin^*

Department of Pathology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005, China

Received:2022-09-23 Revised:2023-02-20 Online:2023-09-05 Published:2023-09-01
Contact: ^*liuyuqin@pumc.edu.cn

摘要/Abstract

摘要： 原发性胃淋巴瘤(PGL)是除胃癌外最常见的胃恶性肿瘤,大多无特异临床症状,所以通常不能被准确诊断,易出现误诊和漏诊。主要治疗方法包括手术、放射治疗、化学药物治疗和靶向治疗,免疫治疗有望成为其潜在治疗方式。了解其诊断过程中存在的难点是准确诊断的保障,也是后续精准治疗的基础。

关键词: 原发性胃淋巴瘤, 误诊, 免疫治疗, 免疫检查点抑制剂

Abstract: Primary gastric lymphoma (PGL) is the most common gastric malignant tumor except gastric cancer, most of which have no specific clinical symptoms. It is usually not accurately diagnosed. And it is prone to misdiagnosis and missed diagnosis. The main treatments include surgery, radiotherapy, chemotherapy and targeted therapy. And the immunotherapy is expected to be a potential treatment modality. Understanding the difficulties in the diagnosis process is the guarantee of accurate diagnosis and the basis for subsequent precision treatment.

Key words: primary gastric lymphoma, misdiagnosis, immunotherapy, immune checkpoint inhibitor

中图分类号:

R735.2

代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.

DAI Di, LIU Yuqin. Diagnostic difficulties and treatment progress of primary gastric lymphoma[J]. Basic & Clinical Medicine, 2023, 43(9): 1462-1466.

参考文献 26

[1]	吕远, 王晓娜, 梁寒. 原发性胃淋巴瘤200例临床分析[J]. 中华胃肠外科杂志, 2012, 15: 157-160.
[2]	Carboni F, Diodoro MG, Valle M. Synchronous primary diffuse large B cell lymphoma and adenocarcinoma of the stomach: a clinical dilemma[J]. Indian J Surg Oncol, 2020, 11: 223-225.
[3]	Meguro M, Someya T, Ohmura T, et al. Collision cancer of primary squamous cell carcinoma and adenocarcinoma in the stomach after treatment for a non-Hodgkin′s lymphoma of diffuse large B cell type:a case report[J]. Nihon Shokakibyo Gakkai Zasshi, 2020, 117: 334-344.
[4]	Fukunaga H, Asama H, Kaneda H, et al. Collision tumor with diffuse large B cell lymphoma and gastric cancer[J]. Jpn J Clin Oncol, 2016, 46: 968-969.
[5]	Kilaru S, Panda SS, Das H, et al. Primary gastric Hodgkin′s lymphoma: a rare coincidence[J]. Cancer Treat Res Commun, 2020, 24: 100194.doi:10.1016/j.ctarc.2020.100194.
[6]	Zhang L, Zhang P, Wen J, et al. Primary gastric natural killer/T-cell lymphoma with diffuse CD30 expression and without CD56 expression: a case report[J]. Oncol Lett, 2016, 11: 969-972.
[7]	Saber MM. Diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20 cells in diffuse Large B-cell lymphoma[J]. Antibodies (Basel), 2022, 11.doi: 10.3390/antib11010015.
[8]	Chen Y, Li M, Cao J, et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression[J]. Open Life Sci, 2021, 16: 909-919.
[9]	American association for cancer research.LAG3-PD-1 Combo impresses in melanoma[J]. Cancer Discov, 2021, 11: 1605-1606.
[10]	Jiang X, Zhang H, Ni J, et al. Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development[J]. Front Oncol, 2022, 12: 1060496.doi: 10.3389/fonc.2022.1060496.
[11]	Nagasaki J, Togashi Y, Sugawara T, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-Ⅱ-expressing tumors such as classic Hodgkin lymphoma[J]. Blood Adv, 2020, 4: 4069-4082.
[12]	Ma J, Pang X, Li J, et al. The immune checkpoint expression in the tumor immune microenvironment of DLBCL: clinicopathologic features and prognosis[J]. Front Oncol, 2022, 12: 1069378.doi: 10.3389/fonc.2022.1069378.
[13]	Morrissey MA, Williamson AP, Steinbach AM, et al. Chimeric antigen receptors that trigger phagocytosis[J]. Elife, 2018, 7.doi: 10.7554/eLife.36688.
[14]	Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells[J]. Cancer Discov, 2021, 11: 1100-1117.
[15]	Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers[J]. ESMO Open, 2022, 7: 100336. doi: 10.1016/j.esmoop.2021.100336.
[16]	Shi Y, Su H, Song Y, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab[J]. EBioMedicine, 2020, 54: 102731.doi: 10.1016/j.ebiom.2020.102731.
[17]	Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors[J]. Nat Med, 2020, 26: 688-692.
[18]	Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396: 839-852.
[19]	Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380: 45-56.
[20]	Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma[J]. Blood, 2021, 137: 2634-2645.
[21]	Albinger N, Pfeifer R, Nitsche M, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia[J]. Blood Cancer J, 2022, 12: 61.doi: 10.1038/s41408-022-00660-2.
[22]	Soldierer M, Bister A, Haist C, et al. Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies[J]. Front Immunol, 2022, 13: 847008. doi: 10.3389/fimmu.2022.847008.
[23]	Mukhopadhyay M. Macrophages enter CAR immunotherapy[J]. Nat Methods, 2020, 17: 561.doi: 10.1038/s41592-020-0862-4.
[24]	Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol, 2020, 38: 947-953.
[25]	Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix[J]. Br J Cancer, 2019, 121: 837-845.
[26]	Kang M, Lee SH, Kwon M, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy[J]. Adv Mater, 2021, 33: e2103258.doi: 10.1002/adma.202103258.

原发性胃淋巴瘤的诊断难点及治疗进展

Diagnostic difficulties and treatment progress of primary gastric lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[2]	葛郁平, 刘莹, 赵林. 血管肉瘤药物治疗进展[J]. 基础医学与临床, 2024, 44(10): 1363-1367.
[3]	杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.
[4]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[5]	伍琦, 王绍波. CRISPR/Cas9技术在CAR-T细胞治疗肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1313-1316.
[6]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[7]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[8]	甘兹颖, 唐慧. 溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展[J]. 基础医学与临床, 2022, 42(4): 651-655.
[9]	斯晓燕, 王汉萍, 张力, 王孟昭, 张晓彤. 免疫检查点抑制剂致细胞因子释放综合征1例[J]. 基础医学与临床, 2022, 42(11): 1764-1766.
[10]	郭晓鹏, 幸兵, 马文斌. 垂体腺瘤免疫微环境及免疫治疗的研究进展[J]. 基础医学与临床, 2022, 42(1): 173-178.
[11]	张若曦, 韩冰. 免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展[J]. 基础医学与临床, 2021, 41(8): 1210-1215.
[12]	李倩, 刘纯华, 王晨怡, 谈娇娇, 马玉萍, 吕海宏. 炎性因子调控1型糖尿病血管内皮细胞功能的研究进展[J]. 基础医学与临床, 2021, 41(10): 1497-1501.
[13]	李佳忆, 幸兵. 免疫检查点抑制剂相关自身免疫性垂体炎的研究进展[J]. 基础医学与临床, 2020, 40(3): 403-406.
[14]	李北芳高霞张朦琦葛赛李忠武沈琳高静. 运用组学手段探索EBV相关性与非相关性胃癌的可能差异分子[J]. 基础医学与临床, 2018, 38(7): 933-937.
[15]	童晨曦宋银宏. 嵌合抗原受体基因修饰的T细胞免疫治疗骨肉瘤的研究进展[J]. 基础医学与临床, 2018, 38(7): 1012-1015.